Target Engagement of a Phosphodiesterase 2A Inhibitor Affecting Long-Term Memory in the Rat

Guibao Gu, Trevor Scott, Yingzhuo Yan, Noelle Warren, Adia Zhang, Ali Tabatabaei, Hao Xu, Kathleen Aertgeerts, Laurent Gomez, Andrew Morse, Yu-Wen Li, J. Guy Breitenbacher, Eben Massari, Jeffrey Vivian, and Anne Danks

Departments of Preclinical Research (G.G., T.S., N.W., A.T., A.M., Y.-W.L., J.V., A.D.), Chemistry Manufacturing and Control (A.Z.), Biology (Y.Y., E.M.), Structural Biology (H.X., K.A.), and Medicinal Chemistry (L.G., J.G.B.), Dart Neuroscience, LLC, San Diego, California

Received December 21, 2018; accepted June 24, 2019

ABSTRACT

Inhibition of phosphodiesterase 2A (PDE2A) has been proposed as a potential approach to enhance cognitive functioning and memory through boosting intracellular cGMP/cAMP and enhancing neuroplasticity in memory-related neural circuitry. Previous preclinical studies demonstrated that PDE2A inhibitors could reverse N-methyl-D-aspartate receptor antagonist (5S,10R)-(−)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine or ketamine-induced memory deficit. Here, we report that the potent and selective PDE2A inhibitor 4-(1-azetidinyl)-7-methyl-5-(1-methyl-5-(4-(trifluoromethyl)-2-pyridinyl)-1H-pyrazol-4-yl)-imidazo[1,2,4]triazine (PF-05180999) enhances long-term memory in a contextual fear conditioning model in the rat at the oral dose of 0.3 mg/kg. Target engagement at this efficacious dose was explored using in vivo autoradiography. Converse to oral dose of 0.3 mg/kg. Target engagement at this efficacious

Introduction

Cognitive decline is one of the most frequent health complaints of healthy individuals as they age, which is even more pronounced in diagnosed neurocognitive disorders such as Alzheimer’s disease, dementia with Lewy body, or frontotemporal dementia (Petersen et al., 1999; Fleischman et al., 2004; Budson and Price, 2005; American Psychiatric Association, 2013). Physiologically, long-term memory relies on the plastic enhancement of specific neural circuitry (Kandel et al., 2014; Poo et al., 2016). The neuronal plasticity requires de novo protein synthesis and the activation of cAMP response element binding protein (CREB) to play a pivotal role in this process (Silva et al., 1998; Tully et al., 2003; Chen et al., 2010; Kandel, 2012). CREB is a transcription factor (Brindle and Montminy, 1992). Phosphorylation of CREB promotes the expression of genes with upstream cAMP response element (CREB) by the PDE2A inhibitor, a paradoxical increase (up to 40%) in PDE2A binding was detected. However, a typical target occupancy curve could be generated by PF-05180999 at much higher doses. In vitro experiments using recombinant PDE2A protein or rat brain homogenate that contains native PDE2A protein demonstrated that increased cGMP after initial PDE2A inhibition could be responsible for the activation of PDE2A enzyme via allosteric binding to the GAF-B domain, leading to positive cooperativity of the dormant PDE2A enzymes. Our results suggest that when evaluating target engagement of PDE2A inhibitors for memory disorder in clinical setting with occupancy assays, the efficacious dose may not fall on the typical receptor/target curve. On the contrary, an increase in PDE2A tracer binding is likely seen. Our results also suggest that when evaluating target occupancy of enzymes, potential regulation of enzyme activities should be considered.

Several intracellular signaling pathways are known to activate CREB, and cAMP and Ca2+ are perhaps the most important regulators (Montminy et al., 1990; Soderling, 1999; West et al., 2001). Similarly, intracellular cGMP can also activate CREB via cGMP-dependent protein kinase (Lu and Ding, 1999; Paul et al., 2010). Therefore, it is conceivable that managing intracellular cAMP, and/or cGMP levels would help manipulate CREB phosphorylation and enhance neural circuitry plasticity (Teich et al., 2015).

The levels of intracellular cAMP and/or cGMP are regulated by phosphodiesterases (PDEs) through hydrolysis to AMP and/or GMP. A family with 11 members, each PDE subtype has multiple isoforms and splice variants (Conti and Beavo, 2007). PDE members are categorized by their catalytic domain selectivity and the properties of their regulatory domains (Schmidt, 2010; Conti and Richter, 2014). As a cGMP-stimulated cyclic nucleotide phosphodiesterase (Martins et al., 1982), phosphodiesterase 2A (PDE2A) hydrolyzes both cAMP and cGMP and possesses an allosteric GAF (cGMP-activated PDEs, adenylyl cyclase, and Fh1A)-B domain that preferentially binds cGMP (Stroop and

https://doi.org/10.1124/jpet.118.255851.

ABREVIATIONS: CFC, contextual fear conditioning; CREB, cAMP response element binding protein; PDE, phosphodiesterase; PDE2A, phosphodiesterase 2A; PEG 400, polyethylene glycol 400; PF-05180999, 4-(1-azetidinyl)-7-methyl-5-[1-methyl-5-[5-(trifluoromethyl)-2-pyridinyl]-1H-pyrazol-4-yl]-imidazo[1,2,4]triazine; PF-05270430, 4-(3-fluoroazetidin-1-yl)-7-methyl-5-(1-methyl-5-(4-(trifluoromethyl)phenyl)-1H-pyrazol-4-yl)imidazo[1,5-f][1,2,4]triazine.
Beavo, 1991; Martinez et al., 2002; Wu et al., 2004; Pandit et al., 2009). Via a positive cooperativity mechanism, cGMP binding to the GAF domain causes a conformational change in the linker region between the catalytic and regulatory domains of the enzyme, swings the H-loops out, opens the access of the substrate, and thereby upregulates the hydrolytic activity of PDE2A (Pandit et al., 2009).

The high abundance and preferential expression in the brain indicates that PDE2A could serve as a suitable target for pharmacological intervention in memory disorders. PDE2A is highly expressed in brain regions that are important for cognitive functions, including the cerebral cortex, hippocampus, and striatum (Stephenson et al., 2012; Kelly et al., 2014). In vitro and in vivo animal studies, PDE2A-selective inhibitors enhanced long-term potentiation and improved the performance of multiple memory tasks (Boess et al., 2004; Domek-Lopacińska and Strosznajder, 2008; Helal et al., 2018; Nakashima et al., 2018).

Critical to the advancement of PDE2A inhibitor drugs in clinic is the identification and validation of specific biomarkers of drug action in the central nervous system. Recently, 4-(3-fluoroazetidin-1-yl)-7-methyl-5-(1-methyl-5-(4-trifluoromethyl)phenyl)-1H-pyrazol-4-yl)imidazo[1,5-f][1,2,4]triazine (PF-05270430) (Chen et al., 2016) was reported to be a useful positron emission tomography ligand. The utility of PDE2A positron emission tomography ligands depends on the establishment of a defined occupancy/efficacy relationship with the desired pharmacological effect. The PDE2A inhibitor N-((1S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide reversed (5S,10R)-(+)5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine—induced episodic memory deficits at oral doses of 3 and 10 mg/kg (but not 1 mg/kg), which corresponded well with the dose that elevated hippocampal cGMP levels, where occupancy was reported to be about 46% and 63% at these doses, respectively (Mikami et al., 2017a). However, N-((1S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide significantly enhanced performance in the rat novel object recognition study (Mikami et al., 2017b) at a dose of 0.1 mg/kg, presumably at occupancy far lower than 46%. Similarly, another PDE2A inhibitor, 4-(1-azetidinyl)-7-methyl-5-[1-methyl-5-[5-(trifluoromethyl)-2-pyridinyl]-1H-pyrazol-4-yl]imidazo[5,1-f][1,2,4]triazine (PF-05180999), demonstrated reversal of ketamine-induced working memory deficits in rats at doses of 0.1–0.32 mg/kg, s.c., corresponding to “several fold less than 50% occupancy” (Helal et al., 2018). The phenomenon of efficacy in rodent memory models at very low occupancy was a common observation in our PDE2A drug discovery efforts (unpublished data).

In evaluating PDE2A target occupancy by PDE2A inhibitors, the positive cooperativity of the enzyme should be considered. Since the doses of the PDE2A inhibitor required to reverse chemical-challenged cognitive deficits were relatively high (Mikami et al., 2017a; Helal et al., 2018), this positive cooperativity might have been masked. In the current study, we used a nonchemically challenged long-term memory retention model and in vivo autoradiography to investigate the target engagement of a potent and selective PDE2A inhibitor, PF-05180999, at the low efficacious doses.

### Materials and Methods

#### Materials

The NIR Video Fear Conditioning System Contextual Package was used (Med Associates, Inc., Vermont). Male CD rats (350–450 g) were obtained from Charles River (Hollister, CA). Rat whole brain membranes (0.6 mg/ml) were used and 3H-PF-05270430 was obtained from Moravek (Brea, CA). Costar 96-well V-bottom dilution plates, Greiner 96-well masterblock (0.5 ml) V-bottom assay plates, and Perkin Elmer 96-well multifilter/GFC filter plates (Boston, MA) were employed.

#### Methods

##### Animals.

The protocols performed in the present rodent studies were approved by the Institutional Animal Use and Care Committee of Dart NeuroScience, LLC, in accordance with the guidelines of the National Institutes of Health and the US Department of Agriculture for the care and use of laboratory animals. Male CD rats, naive or jugular vein–cannulated, weighing from 100 to 450 g, were obtained from Charles River Laboratories and housed in cages on a 12 hours light/dark cycle. Food and water were available ad libitum.

##### Drugs.

The drugs used included PF-05180999, PDE2A (IC_{50} = 1.6 nM, >56,250-fold selectivity of PDE2A over PDE1B1, PDE3A1, PDE4D3, and PDE5A1), and bovine PDE6 (26,969-fold over PDE7B; >56,250-fold over PDE5B and PDE9A1; 2030-fold over PDE10A; and 50,090-fold over PDE11A4) (Helal et al., 2018) made by Dart NeuroScience, LLC (San Diego, CA), as well as 3H-PF-05270430, PDE2A (IC_{50} = 0.53 nM, >56,604-fold selectivity for PDE2A over PDE1B, >56,604-fold over PDE3A and PDE4D, 49,057-fold over PDE5A, >18,688-fold over PDE6A, 22,642-fold over PDE7B, >18,868-fold over PDE8B and PDE9A, 7358-fold over PDE10A, and >18,868-fold over PDE11) (Zhang, 2013), made by Dart NeuroScience, LLC, and Moravek Biochemicals. PF-05180999 was freshly prepared in 10:40:50 or 10:60:30 PEG 400 (PEG 400):H2O solution. 3H-PF-05270430 was freshly prepared in a solution of 50:30:20 PEG 400:H2O:ethanol.

##### Contextual Fear Conditioning Task.

The contextual fear conditioning (CFC) task was performed in a conditioning chamber placed in a sound-attenuating box (Med Associates Inc.) during the light phase of the cycle. CD male rats, weighing from 350 to 450 g, were doubly housed in the holding room for 2 weeks prior to training/test. One hour after receiving an oral dose of vehicle (10:40:50; N-methyl-2-pyrrolidone:polyethylene glycol 400 (PEG 400):H2O solution. 3H-PF-05270430 was freshly prepared in a solution of 50:30:20 PEG 400:H2O:ethanol.

##### Radioactive Tracer Labeling.

PF-05270430 was labeled with tritium as the PDE2A ligand by Moravek Biochemicals. The ligand
was radiolabeled from the cold compound synthesized by the Department of Chemistry, Dart Neurosciences, LLC, by a direct exchange of hydrogen atoms with its isotope tritium using Crabtree's catalyst and tritium gas under anhydrous conditions. The reaction was stirred at room temperature for 24 hours. The crude product was dissolved in ethanol and evaporated to dryness three times. The radioligand was purified on a HPLC-C18 Capcell Pak column (mobile phase: 45% acetonitrile and 0.1% trifluoroacetic acid; UV: 254 nm; flow rate: 6 ml/min). A radiochemical purity of over 99.3% and specific activity of over 87 Ci/mmol were achieved. The tritium tracer was then packaged in 100% ethanol and stored at −20°C before use.

**Rat Brain Membrane Preparation.** Naive rats were deeply anesthetized with isoflurane vapor in a Bell jar and brains quickly removed from the skull and immediately frozen in isopentane bath chilled with dry ice. Frozen brains were then stored in a freezer at −80°C before use. During membrane preparation, whole flash-frozen rat brains were thawed on ice and split into two halves down the midline. Each half was added to a 15-ml centrifugation tube containing 7 ml of ice-cold assay buffer [50 mM Tris HCl, 1 mM MgCl2, 1 mM CaCl2, and 2 mM KCl (pH 7.4)]. Brains were further homogenized on ice using the Omni Prep Multi Sample Homogenizer at 14,000 rpm for 90 seconds. After homogenization, samples were centrifuged at 15,000g for 30 minutes. The supernatant was discarded and the pellet was resuspended in 7 ml of ice-cold assay buffer. Resuspended membranes were then pooled together and kept on ice. Following the determination of the total protein concentration using the Bio-Rad Protein Assay kit, 1 ml aliquots were made, frozen on dry ice, and stored at −80°C before use.

**K<sub>i</sub> and B<sub>max</sub> Determination.** The dissociation constant at equilibrium K<sub>i</sub> and maximum number of binding sites B<sub>max</sub> values of the radiolabeled tracer were measured with rat brain homogenate. Binding reactions were set up in a 96-well assay plate (156 µg/well total protein). Various concentrations of [3H]-radioligand in the absence (for total binding) or presence (for nonspecific binding) of 10 µM unlabeled form of the ligand were incubated with rat brain homogenate protein at room temperature for 2 hours. The assay solutions were then filtered using a Brandel Harvester onto a 96-well GF/C filter plate. The filter plate was washed using 21 ml of wash buffer [50 mM Tris HCl and 1 mM MgCl2 (pH 7.4)]. After drying, each well of the filter was added to 50 ml of Microscint-20 scintillation fluid and the plate was counted with a MicroBeta counter (Perkin Elmer). The specific binding was calculated by subtracting the nonspecific binding from the total binding for each concentration used in the assay and the data were fit to a one-site-specific binding curve using GraphPad Prism software (GraphPad, Inc., San Diego, CA). The B<sub>max</sub> value was calculated using GraphPad Quick Calecs based on the specific activity of the radioligand, microbeta counter efficiency (43%), and total protein concentration (156 µg/well).

**K<sub>i</sub> Assay.** An in vitro K<sub>i</sub> assay was performed to examine displacement of the radiolabeled PDE2A tracer by PF-05180999. Compound PF-05180999 was first serially diluted, ranging from 0.05 nM to 50 µM in duplicate with 0.5% DMSO/assay buffer in a 96-well 0.5 ml V-bottom assay plate; total binding or nonspecific binding controls were placed in the wells by skipping the test article or adding 10 µM of the unlabeled form of the radioligand in the 0.5% DMSO/assay buffer. [3H]-PF-05270430 at the concentration of K<sub>i</sub> and 156 µg/total well protein of the membrane prep was added into each well and incubated for 2 hours at room temperature with slow agitation. The assay solutions were harvested and the counts were measured following the procedures described previously. The specific binding was calculated by subtracting the nonspecific binding from the total binding for each concentration used in the assay. The IC<sub>50</sub> value was determined and the 11-point inhibition curve was plotted using GraphPad Prism software. The IC<sub>50</sub> values were converted to K<sub>i</sub> values according to the Chang-Prusoff equation: K<sub>i</sub> = IC<sub>50</sub>/1 + [S]/K<sub>app</sub>, where [S] = K<sub>app</sub>.

**In Vivo PDE2A Occupancy.** An in vivo autoradiography method was used to explore PDE2A target occupancy in the rat by PF-05180999. The radioactive tracer [3H]-PF-05270430 was first characterized in live animals by intravenous dosing into jugular vein-cannulated CD rats weighing from 100 to 150 g to identify the proper dose and time point at which the radioactivity of the region of interest for the tracer reached 0.5–1.0 cpm/mm<sup>2</sup> and the best signal-to-noise ratio (region of interest/reference region) was achieved. In the in vivo occupancy experiments, 0.03–150 mg/kg PF-05180999 or vehicle (10:40:50 or 10:60:30 N-methyl-2-pyrrolidinone:PEG 400:H<sub>2</sub>O) was orally dosed. Fifty minutes later, approximately 300 µl blood was drawn from the jugular cannula and collected in tubes with a lithium heparin gel barrier (Terumo Corporation, Somerset, NJ). Plasma was prepared by centrifugation for compound concentration analysis. Immediately following plasma collection, rats then received a total volume of 600 µl tritiated tracer (0.5 µCi/g or 1 µCi/g per body weight, in 50% PEG 400, 20% ethanol, and 30% H<sub>2</sub>O) vehicle) into the jugular vein, followed by 500 µl saline flush. Injections lasted at least for 30 seconds to avoid circulatory failure. Ten minutes later, following anesthesia with isoflurane in a Bell jar, each rat was decapitated, 500 µl of trunk blood was collected in tubes with lithium heparin gel barrier, and plasma was isolated by centrifugation for radioactivity quantitation. Brain tissue from each rat was quickly removed, frozen in dry ice-chilled isopentane, and stored at −80°C before further processing. Sagittal brain sections were cut at 20 µm with a Leica CM1950 cryostat and mounted on Superfrost Plus slides. After drying at room temperature, slides were imaged with a Beta-Imager (BioSpace Laboratory). The acquired images were then analyzed with M3Vision software. The occupancy values were calculated as follows: % occupancy = (vehicle binding – drug binding)/vehicle binding × 100. The nondisplaceable signals in the reference region, referred to as the nonspecific binding, were subtracted from all values prior to the calculation. Negative values were excluded in occupancy-exposure curve plotting.

**In Vitro Recombinant PDE2A Protein Binding.** To elucidate the role of cGMP activation produced by PDE2A inhibition, an in vitro binding assay was developed using a recombinant PDE2A protein. The cDNA corresponding to residues 215–900 of human PDE2A3 (UniProt entry: O004048), followed by a tobacco etch virus protease cleavage site, a 10X polyhistidine tag, and a FLAG tag, was synthesized, codon optimized (DNA2.0; Neward, CA), and subcloned into a modified pFastbac1 vector (Thermo Fisher Scientific, Waltham, MA). High titer recombinant baculoviruses (>10<sup>8</sup> infectious viral particles per milliliter) were generated using the Bac-to-Bac Baculo-Virus Expression System (Thermo Fisher Scientific) and used to infect Spodoptera frugiperda insect cells at a density of 2 × 10<sup>4</sup> cells/ml with high titer viral stock at a multiplicity of infection of 5. Infected cells were grown at 27°C for 48–96 hours prior to being harvested, and the cell pellets were stored at −80°C. Then, 2.5 l of frozen cells was broken into small pieces and resuspended into 200 ml lyser buffer [50 mM Tris (pH 7.5), 800 mM NaCl, 5% glycerol, 0.25 mM tris(2-carboxyethyl)phosphine, and one tablet of a protease inhibitor cocktail (Roche)]. After centrifugation, the sample was passed through a cheese cloth. Twenty microliters of Universal Nuclease (Thermo Fisher Scientific) and 9 ml of a Probond Ni Resin (Thermo Fisher Scientific) were added to the sample and incubated for 3 hours. Gravity-assisted flow was used to wash the resin with 300 ml of 50 mM Tris (pH 7.5), 600 mM NaCl, 5% glycerol, and 20 mM imidazole. The protein was then eluted with seven column volumes (~25 ml) of 50 mM Tris (pH 7.5), 600 mM NaCl, 5% glycerol, and 300 mM imidazole. The protein was then further purified by size-exclusion chromatography using a Superdex 200 column (GE Healthcare Life Sciences) with a flow of 1 ml/min using a buffer containing 25 mM Hepes (pH 7.5), 50 mM NaCl, and 0.25 mM tris(2-carboxyethyl)phosphine. The fractions with the desired retention time were pooled. The final protein concentration was 0.56 mg/ml.

**cGMP Regulation of PDE2A Ligand Binding.** PDE2A (215–900) protein (1 mM) was incubated with 10 nM [3H]-PF-05270430 and various concentrations of cGMP (0–100 mM) in assay buffer [25 mM Tris HCl (pH 7.4), 5 mM MgCl2, 0.2% bovine serum

Downloaded from jpet.aspetjournals.org at ASPET Journals on September 13, 2023.
aluminum, 0.5 mM 1,4-dithiothreitol, and 0.05% Tween-20) at room temperature for 1 hour in 96-well nonbinding surface plates (Corning). PDE2A was subsequently captured by addition of 1:4 dilution of ANTI-FLAG M2 Affinity Gel (Sigma) prepared in assay buffer, incubated for an additional 1 hour at room temperature, and then transferred to glass fiber filter plates (UniFilter-96 GFC Microplate; Perkin Elmer Life Sciences) that were presoaked in 0.5% polyethyleneimine solution. Filters were washed six times with wash buffer (50 mM Tris (pH 7.5), 5 mM MgCl₂, and 1 mM EDTA) using the Brandel Harvester and the remaining radioactivity was quantified using a Microbeta Trilux counter (Perkin Elmer Life Sciences). Nonspecific binding was determined in the presence of 10 μM PF-05270430 and 100 μM cGMP.

**Kₐ and B_max Determination in the Presence or Absence of cGMP.** In a 96-well nonbinding surface plate, 1 nM of PDE2A (215–900) protein and various concentrations of ³H-PF-05270430 (0–200 nM) were incubated in assay buffer (25 mM Tris HCl (pH 7.4), 5 mM MgCl₂, 0.2% bovine serum albumin, 0.5 mM 1,4-dithiothreitol, and 0.05% Tween-20) or assay buffer containing 30 μM cGMP at room temperature for 1 hour. PDE2A protein capture, washing, and counting of the remaining radioactivity were performed as described previously. The Kₐ and B_max values were determined in GraphPad Prism 7 by fitting the data using a one-site model.

**In Vitro Native PDE2A Protein Binding in the Absence or Presence of cGMP.** In vitro PDE2A binding in the absence or presence of cGMP was examined with native PDE2A protein in rat brain homogenate, as prepared previously. Then, 0.1 mg/ml protein was incubated with 0.5 nM ³H-PF-05270430 and various concentrations of cGMP (0–10 mM) in assay buffer (50 mM Tris HCl, 1 mM MgCl₂, 1 mM CaCl₂, and 2 mM KCl (pH 7.4)) at room temperature for 5 minutes in 96-well nonbinding surface plates (Corning). In the presence of 10 μM PDE10 inhibitor 2-(4-(1-methyl-4-pyridin-4-yl)-4H-pyrazol-3-yl)phenoxymethyl)quinoline and a PDE1 inhibitor. Nonspecific binding was determined in the presence of 10 μM PF-05270430 and 100 μM cGMP. The assay solutions were then filtered using the Brandel Harvester onto a 96-well GF/C filter plate. After washing and drying the filter plate, 50 ml of Microscint-20 scintillation fluid was added to each well of the filter and the plate was counted with a MicroBeta counter (PerkinElmer Life Sciences).

**Statistical Analysis.** Data acquired were analyzed using GraphPad Prism 7.0. All data are presented as mean with S.E.M. The statistical significance of the data was analyzed using one-way ANOVA with Bonferroni’s post hoc test. A P value of less than 0.05 is defined as significant. Graphs were plotted using Prism software.

**Results**

**Characterization of Kₐ and B_max Values of ³H-PF-05270430 with Rat Brain Homogenate and Brain Sections, Binding of PDE2A.** PF-05270430 was reported to be highly selective and potent. In a cGMP-stimulated human recombinant full-length PDE2A enzymatic activity assay, its IC₅₀ value was 0.53 nM (Zhang et al., 2013). Based on its favorable profile of brain penetration, efflux, and plasma/brain free fraction, the compound was advanced, labeled with ¹⁸F, and successfully used in positron emission tomography imaging studies in cynomolgus monkeys and humans (Zhang et al., 2013; Chen et al., 2016; Naganawa et al., 2016). In the current study, after tritiation, ³H-PF-05270430 maintained its high potency and selectivity. The tracer yielded over 95% specific binding with rat brain homogenate, with a Kₐ value of 9.4 nM, a 10- to 20-fold shift compared with the in vitro functional enzymatic activity. The B_max value was 1515 fmol/mg (Fig. 1A). Incubation of the tracer (10 nM for 1 hour at room temperature) with rat brain sections demonstrated a distinctive PDE2A binding pattern (Fig. 1B), consistent with the pattern of PDE2A expression in the brain (Stephenson et al., 2012; Kelly et al., 2014). In the rat brain, high density of the PDE2A binding signals was observed in the olfactory bulb, olfactory tubercle, cortex, hippocampus, striatum, ventral tegmental area, as well as the substantia nigra. On coronal sections (data not shown), in the striatum, higher density of binding signals was found in the globus pallidus than in the caudate putamen.

**Establishing an Exposure-Occupancy Relationship for PF-05180999 at the Higher Dose Range.** After characterization of the radioligand we established an occupancy dose response for PF-05180999 between the doses of 1 and 150 mg/kg. A dose-dependent curve was generated against the total plasma concentration of the compound (Fig. 2A), with a slope of around 1 and IC₅₀ (50% occupancy) of 965.8 nM total plasma concentration of the compound. The 50% occupancy value, when backcalculated based on the compound’s brain penetration, free plasma, and free brain percentage, was 122.7 nM, which is largely consistent with the in vitro Kₐ assay value (49.0 nM) using rat brain homogenate (Fig. 2B). The plasma radioactivity levels at the time when brains were harvested looked constant; no dose-dependent increase or decrease was observed (Fig. 2C). However, because each treatment group only had two rats, statistical analysis was not possible.

**Efficacy of PF-05180999 in the CFC Rat Model.** To characterize the efficacy of PF-05180999, we choose to perform a model of long-term memory that did not involve the use of chemical impairment. In this case, the 24-hour conditioned fear test was used. Pretreatment with an oral dose of PF-05180999 at the dose of 0.3 mg/kg prior to training, which consisted of 2.04 mA unconditioned footshocks in the training context, produced a significant increase in the rate of freezing behavior 24 hours later compared with vehicle-dosed animals. Doses at 0.03 or 1 mg/kg were not efficacious, suggesting an inverted U-shaped dose effect (Fig. 3). Interestingly, this dose corresponded well to the previously reported reversal of ketamine working memory impairment reported by Pfizer (Helal et al., 2018).

**In Vivo PDE2A Binding following the Lower Dose Range of PF-05180999.** In vivo autoradiography was performed to investigate target engagement by PF-05180999 at the efficacious dose range in the CFC behavior assay. Interestingly, instead of displacing and thereby decreasing PDE2A tracer binding, lower doses of PF-05180999 appeared to increase the tracer binding, and this increased binding tended to return to baseline beyond 3 mg/kg (Fig. 4, A and B). The increased PDE2A binding does not appear to be the result of increased brain entry of the radioactive tracer since the plasma radioactivity levels remained constant at the time when the brain samples were harvested (Fig. 4C). Total plasma concentration of the drug ranged from 10 to 100 nM (Table 1). Since there were only two to four rats per group in the first occupancy study and the increase in PDE2A values appeared to be variable, which made one-way ANOVA analysis treacherous, a separate study with increased n number per group was performed. PF-05180999 at the oral dose of 0.3 mg/kg significantly increased PDE2A tracer binding in vivo compared with the vehicle-control group (Fig. 5), confirming the results in the previous observation.
The dose response was repeated in the other two separate experiments. The pattern of the PDE2A binding following lower doses of PF-05180999 was established after combining the data from all four experiments (Fig. 6).

In Vitro PDE2A Ligand Binding in the Absence or Presence of cGMP. The increased local cGMP levels produced by the lower doses of PDE2A inhibitors were suspected to cause the increase in PDE2A tracer binding. To test this hypothesis, in vitro PDE2A binding in the presence or absence of various concentrations of cGMP was examined using near full-length or catalytic-domain recombinant PDE2A protein or natural PDE2A enzyme in rat brain homogenate. cGMP dosedependently increased PDE2A tracer binding to the near full-length PDE2A recombinant enzyme protein (the activation phase). This facilitation plateaued when cGMP reached 10–100 μM. However, when the cGMP concentration continued to rise above 100 μM, PDE2A binding decreased in a dose-dependent pattern (the inhibition phase) (Fig. 7). With the catalytic domain alone, such a dual cGMP effect disappeared; only the inhibition phase was present (data not shown). Similarly, cGMP also showed a dual-phase effect with the natural PDE2A protein in the rat brain homogenate in the presence of 10 μM PDE1 and PDE10 inhibitors. The activation effect plateaued at the concentration of 3–16 μM before the inhibition phase kicked in (Fig. 8). The cGMP-induced activation of PDE2A binding appeared to be due to the increase in PDE2A affinity. In the presence of the fixed concentration of 30 μM cGMP, the PDE2A binding curve shifts to the left. Compared with the control, the $K_d$ value decreased from 17.2 to 2.4 nM, an increase of 7.2-fold in affinity (Fig. 9).

Discussion

The current study demonstrated that the potent and selective PDE2A inhibitor PF-05180999 enhances long-term memory in a contextual fear conditioning model in the rat at the oral dose of 0.3 mg/kg. However, the target engagement study using in vivo autoradiography failed to show a decrease...
in PDE2A binding (target occupancy) at this efficacious dose. Instead, a paradoxical, up to 40% increase in PDE2A binding was detected. At higher doses, this compound did decrease PDE2A binding and an occupancy curve against plasma concentration could be generated.

A similar occupancy curve by PF-05180999 has been reported by Chen et al. (2016) in the cynomolgus monkey. Using the same PF-05270430 compound as the tracer (18F-labeled), the authors reported a half-maximal effective plasma concentration of 69.4 ng/ml in the region of the striatum (equivalent to 167.5 nm), several fold more potent than what we saw in the rat. This potency mismatch may stem from the differences of species and/or methods used in the experiment and data analysis.

The efficacious dose of the compound in the rat CFC model in the present study overlaps with the dose causing the increase of PDE2A binding capacity. However, it should not assume that the memory enhancement effect by PF-05180999 is due to the activation of PDE2A rather than inhibition of the enzyme. Since the PF-05180999 compound itself does not directly activate PDE2A, as it failed to increase the binding of the recombinant enzyme in the absence of cGMP at various concentrations (Y. Yan, unpublished data), the increased PDE2A binding capacity appears to be due to the increased level of cGMP (the product of phosphodiesterase 2 enzyme inhibition). Our in vitro studies confirmed that cGMP does cause the allosteric modulation of the enzyme itself, as demonstrated by the increase in the tracer binding in both recombinant and natural PDE2A proteins. Increased cGMP at the appropriate levels also activates its downstream kinases and the intracellular cascade and enhances long-term memory in the rat CFC model.

Receptor/target occupancy has been widely used as a platform to explore target engagement for targets such as G-protein–coupled receptors (Kapur et al., 1995; Hargreaves, 2002; Yokoi et al., 2002; Raddad et al., 2016) and transporters (Martin-Facklam et al., 2013; Finnema et al., 2015) in drug discovery and development. Efforts have been made to demonstrate target occupancy for enzymes (Freedman et al., 2005; Delnomdedieu et al., 2017) as well. For some enzymes, one problem for occupancy studies is the cooperativity of the endogenous substrate with the enzyme itself when the compound investigated is the enzyme inhibitor. This cooperativity can change the affinity of the enzyme and significantly

![Fig. 3. PF-05180999 enhances long-term memory in the CFC model in the rat. Mean percentage of freezing (±S.E.M.) during the 3-minute contextual fear memory test. PF-05180999 dosed at 0.3 mg/kg enhanced long-term contextual fear memory compared with the vehicle-treated two unconditioned stimulus (2US) control rats. Rats (n = 32/group) were dosed (by mouth, 2 ml/kg, vehicle = 10:40:50 (N-methyl-2-pyrrolidone:PEG 400: H2O or PF05180999)) 60 minutes prior to training (which consisted of 2 0.4 mA footshocks in the training context). Contextual fear memory was tested 24 hours after training. Asterisk = P < 0.05 vs. 2US vehicle (ANOVA, least-mean-square post hoc comparison).](image)

![Fig. 4. PDE2A target binding following the lower oral range (0.03–3 mg/kg) of PF-05180999 in the rat. (A and B) PF-05180999 significantly increased PDE2A tracer binding at the dose of 0.3 mg/kg and the binding intensity tended to return to baseline when the doses of the drug were increased (n = 3 per group). (C) Plasma radioactivity levels remained constant 10 minutes after 0.5 μCi/g intravenous injection of the tracer right before the brain samples were harvested. cpm, counts per minute; DPM, disintegrations per minute.)](image)

![TABLE 1 Plasma drug concentration following low oral doses of PF-05180999](table)

<table>
<thead>
<tr>
<th>mg/kg</th>
<th>nM</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.03</td>
<td>BQL</td>
</tr>
<tr>
<td>0.3</td>
<td>14.2</td>
</tr>
<tr>
<td>1</td>
<td>38.2</td>
</tr>
<tr>
<td>3</td>
<td>110.0</td>
</tr>
</tbody>
</table>

BQL, below the quantification limit.
change the occupancy-pharmacodynamic relationship as revealed in the present study.

As demonstrated in the present study, the positive cooperativity by increased cGMP is suggested as the reason for the PDE2A inhibitor–induced increase in PDE2A binding site availability. The major substrate of PDE2A cGMP not only binds to the catalytic domain, but also allosterically binds, with higher affinity, to the GAF-B domain (Wu et al., 2004), leading to increased affinity in the PDE2A enzyme through conformational changes of the binding pocket in the catalytic subunit (Martins et al., 1982; Pandit et al., 2009). It is our understanding that, under normal circumstances, only a small portion of the PDE2A pool is activated by endogenous cGMP in the rat brain, and thus only a fraction of the high-affinity binding sites is available to the ligand. Inactivated PDE2A enzymes have very low binding affinity. When the animals are dosed with PDE2A inhibitor, increased levels of cGMP will spill over to the adjacent inactive PDE2A pool, opening the active sites to increase the affinity of those enzymes and causing an increase in the total binding capacity. If, at this time, there is not enough compound nearby (in quantity or potency, or both), an increase in PDE2A binding is observed. This resembles the activation phase that Pandit et al. (2009) had proposed in an experiment investigating $^3$H-5′-GMP binding in the presence of ascending concentrations of cold cGMP.

Depending on the potency (the $K_i$ value) of the compound, the activation phase could be narrow or wide. After testing over two dozen orally bioavailable, brain-penetrant PDE2A inhibitors, we found that, except for one compound that has extraordinarily high brain exposure, lower affinity compounds with $K_i$ values higher than 50 nM normally have a wide activation phase, and they cause an increase in PDE2A binding site availability at oral doses of 1–100 mg/kg. The higher dose of the compound is needed to fill in the expanded binding capacity for the demonstration of regular target occupancy. Conversely, higher affinity compounds with $K_i$ values less than 50 nM can yield a regular dose-dependent PDE2A target occupancy profile at the 1–100 mg/kg dose range, and the negative phase can only be seen in the very low end of the dose range.

The results of our in vitro binding studies in the presence or absence of cGMP support the role of cGMP in the activation of PDE2A. These results are consistent with previous PDE2A enzymatic velocity studies (Martins et al., 1982; Pandit et al., 2009). Under in vivo conditions, compounds that generate cGMP in the brain via acting on other targets also facilitate PDE2A binding. We (unpublished data) and others (Megens et al., 2017) found that a subcutaneous dose of the PDE10 inhibitor MP-10 could increase in vivo PDE2A binding by 3- to 7-fold. This increase was abolished by pretreatment with NG-Nitro-L-arginine methyl ester, a nonselective nitric oxide synthase inhibitor that blocks the production of cGMP (Megens et al., 2017). In another study (unpublished data), we found that an intraperitoneal dose of ketamine could also significantly increase in vivo PDE2A binding, possibly via a ketamine-induced increase in cGMP in the rat brain (Liebenberg et al., 2015).

The activation of PDE2A following enzyme inhibition appears to be consistent with the roles of PDEs. Under physiologic states, after the system is activated, the increased intracellular cAMP or cGMP is cleaved by PDEs to allow the system to return to the baseline state, and thus get ready for the next round of activation. Higher levels of cyclic nucleotide require higher activity of the enzyme, which could be an increase in the binding affinity of the existing enzymes and/or
an increase in the total activated forms of the enzymes. This activation may not necessarily be a direct effect on the enzyme, such as in PDE2A; it could be an indirect via other intracellular pathways. For example, the activity of PDE1 is dependent on activated Ca²⁺-calmodulin in the cell (Kakkar et al., 1999). PDE4 inhibition–induced increase of cAMP activates phosphokinase A, which in turn phosphorylates PDE4. Phosphorylated PDE4 has higher enzymatic activity (Itoh et al., 2010; Song et al., 2016). The direct action of cGMP on PDE2A enzyme protein may be associated with faster and more efficient activation, indicative of a frontline status of PDE2A in the PDE family (Polito et al., 2013) in coping with increased cGMP in the brain. The reserve of PDE2A appears to be ample since only about 20% of the PDE2A is active under systemic PDE2A inhibitor administration. One of the important reasons is the lack of information on cGMP following systemic PDE2A inhibitor administration. One of the important reasons is the lack of information on cGMP following systemic PDE2A inhibitor administration. One of the important reasons is the lack of information on cGMP following systemic PDE2A inhibitor administration. One of the important reasons is the lack of information on cGMP following systemic PDE2A inhibitor administration. One of the important reasons is the lack of information on cGMP following systemic PDE2A inhibitor administration. One of the important reasons is the lack of information on cGMP following systemic PDE2A inhibitor administration. One of the important reasons is the lack of information on cGMP following systemic PDE2A inhibitor administration. One of the important reasons is the lack of information on cGMP following systemic PDE2A inhibitor administration. One of the important reasons is the lack of information on cGMP following systemic PDE2A inhibitor administration. One of the important reasons is the lack of information on cGMP following systemic PDE2A inhibitor administration. One of the important reasons is the lack of information on cGMP following systemic PDE2A inhibitor administration. One of the important reasons is the lack of information on cGMP following systemic PDE2A inhibitor administration. One of the important reasons is the lack of information on cGMP following systemic PDE2A inhibitor administration. One of the important reasons is the lack of information on cGMP following systemic PDE2A inhibitor administration. One of the important reasons is the lack of information on cGMP following systemic PDE2A inhibitor administration. One of the important reasons is the lack of information on cGMP following systemic PDE2A inhibitor administration. One of the important reasons is the lack of information on cGMP following systemic PDE2A inhibitor administration. One of the important reasons is the lack of information on cGMP following systemic PDE2A inhibitor administration. One of the important reasons is the lack of information on cGMP following systemic PDE2A inhibitor administration. One of the important reasons is the lack of information on cGMP following systemic PDE2A inhibitor administration. One of the important reasons is the lack of information on cGMP following systemic PDE2A inhibitor administration. One of the important reasons is the lack of information on cGMP following systemic PDE2A inhibitor administration. One of the important reasons is the lack of information on cGMP following systemic PDE2A inhibitor administration. One of the important reasons is the lack of information on cGMP following systemic PDE2A inhibitor administration. One of the important reasons is the lack of information on cGMP following systemic PDE2A inhibitor administration. One of the important reasons is the lack of information on cGMP following systemic PDE2A inhibitor administration. One of the important reasons is the lack of information on cGMP following systemic PDE2A inhibitor administration. One of the important reasons is the lack of information on cGMP following systemic PDE2A inhibitor administration. One of the important reasons is the lack of information on cGMP following systemic PDE2A inhibitor administration. One of the important reasons is the lack of information on cGMP following systemic PDE2A inhibitor administration. One of the important reasons is the lack of information on cGMP following systemic PDE2A inhibitor administration. One of the important reasons is the lack of information on cGMP following systemic PDE2A inhibitor administration. One of the important reasons is the lack of information on cGMP following systemic PDE2A inhibitor administration. One of the important reasons is the lack of information on cGMP following systemic PDE2A inhibitor administration. One of the important reasons is the lack of information on cGMP following systemic PDE2A inhibitor administration. One of the important reasons is the lack of information on cGMP following systemic PDE2A inhibitor administration. One of the important reasons is the lack of information on cGMP following systemic PDE2A inhibitor administration. One of the important reasons is the lack of information on cGMP following systemic PDE2A inhibitor administration.